Phacilitate Talks Phacilitate

In this bonus episode of Phacilitate Talks, recorded LIVE at Advanced Therapies Connect (September 2021), Georgi Makin speaks to Amritha Jaishankar, Executive Director at Maryland Stem Cell Research Fund. 
This investment and funding Spotlight episode focuses on the past year of high investment, Women in Advanced Therapies and what to expect from Amritha at Advanced Therapies Connect later today. 
It's not too late to join us! Register and join the conversation via: https://bit.ly/3CSHZKX 
QUICK LINKS: 
Georgi Makin: https://bit.ly/3iefkYZ
Amritha Jaishankar: https://bit.ly/3zMkG3z 

In this bonus episode of Phacilitate Talks, recorded LIVE at Advanced Therapies Connect (September 2021), Georgi Makin speaks to Miguel Forte, CEO at Bone Therapeutics and Magali Taiel, CMO at GenSight Biologics. 
This European Spotlight episode focuses on unique challenges in the industry in Europe, as well as what each speaker will be discussing at the event. 
It's not too late to join us! Register and join the conversation via: https://bit.ly/3zLP3qH
QUICK LINKS: 
Georgi Makin: https://bit.ly/3iefkYZ
Miguel Forte: https://bit.ly/2Ya7U1P
Magali Taiel: https://bit.ly/3ofQGei

The third episode of season 2 of Phacilitate Talks allows us to finally visit a financial theme as we pitch private equity against strategics… 
Watch the full episode via the Phacilitate website: https://bit.ly/3nTtxy1  
Welcome to the third episode of season 2 of Phacilitate Talks! This week, we are finally able to re-visit our schedule as we discuss the financial landscape advanced therapies, pitching private equity against strategics.  
As we continue our journey on the road to Miami, Phacilitate Editor, Georgi Makin, and CEO of Dark Horse Consulting, Anthony Davies, invite guests to discuss key issues in the cell and gene therapy industry, asking the big questions that everyone wants the answer to.   
Find out more about Advanced Therapies Week 2022: https://bit.ly/3my6QyG  
IN THE BLUE CORNER… 
In this episode, Anthony and Georgi are joined by Phil Vanek, CTO at Gamma Biosciences, and Joe LaPlume, Corporate Executive Vice President at Charles River Laboratories.  
The group discusses how the different companies operate, the importance of financial modelling, key headlines from a year of high investment, and how the two different companies or strategies might be able to work together before ‘going shopping’ for the perfect next opportunity for investment.  
QUICK LINKS 
Phil Vanek: https://bit.ly/2W5g1fe  
Joe LaPlume: https://bit.ly/3ksD8d0 
Anthony Davies: https://bit.ly/3B7EQpJ    
Christina Fuentes: https://bit.ly/2YSihaL   
Georgi Makin: https://bit.ly/3jbg5Tj  
The opinions expressed in this podcast are solely those of the interviewees’ and do not necessarily reflect the views or opinions of their respective employers. 
This podcast has been produced in partnership with Dark Horse Consulting: https://darkhorseconsultinggroup.com/    

For the second episode of season 2 of Phacilitate Talks, we interrupt planned transmission to discuss the future of AAV with Nicole Paulk, following the recent FDA AdComm.
Welcome to the second episode of season 2 of Phacilitate Talks! This week, we interrupt planned transmission to discuss the future of AAV following the FDA AdComm in early September.
Watch the full episode via the Phacilitate website: https://bit.ly/3hrQVP3
As we continue our journey on the road to Miami, Phacilitate Editor, Georgi Makin, and CEO of Dark Horse Consulting, Anthony Davies, invite guests to discuss key issues in the cell and gene therapy industry, asking the big questions that everyone wants the answer to. 
Find out more about Advanced Therapies Week 2022: https://bit.ly/3my6QyG 
In this second episode, Anthony and Georgi are joined by Nicole Paulk, AAV Gene Therapy Professor at UCSF, as they discuss reactions to the AdComm meeting, and what we should expect from AAV in the future.
The group discusses a perhaps unfair perception of AAV, novel technologies poised to advance the field, empty capsids, and what guidance is needed to help progress AAV.
QUICK LINKS
Nicole Paulk: https://bit.ly/3k65vxA 
Anthony Davies: https://bit.ly/3B7EQpJ 
Christina Fuentes: https://bit.ly/2YSihaL 
Georgi Makin: https://bit.ly/3jbg5Tj 
The opinions expressed in this podcast are solely those of the interviewees’ and do not necessarily reflect the views or opinions of their respective employers.
This podcast has been produced in partnership with Dark Horse Consulting: https://darkhorseconsultinggroup.com/  

Season 2 of Phacilitate Talks kicks off with a bang as Bruce Levine and Audrey Greenberg explore key questions associated with building capacity, acquiring talent and looking ahead in a post-pandemic world.  
Welcome to season 2 of Phacilitate Talks! This season, we have left the pandemic norm and returned to offices, in-person meetings and even live events!  
Watch the full video via the Phacilitate website: https://bit.ly/3kn7Naf  
As we begin our journey on the road to Miami, Phacilitate Editor, Georgi Makin, and CEO of Dark Horse Consulting, Anthony Davies, invite guests to discuss key issues in the cell and gene therapy industry, asking the big questions that everyone wants the answer to.  
Find out more about Advanced Therapies Week 2022: https://bit.ly/3my6QyG 
In this first episode, Anthony and Georgi are joined by Bruce Levine, Barbara and Edward Netter Professor in Cancer Gene Therapy at the University of Pennsylvania, and Audrey Greenberg, Co-Founder, Discovery Labs & Centre for Breakthrough Medicines, as they discuss the future of cell and gene therapy.  
The group discusses different models for CDMO capacity expansion, acquiring appropriate talent to manage expansion opportunities and the resulting ripple effect and rapid development in the field following multiple, recent high-profile mergers and acquisitions.   
 
*Bonus footage – “Are you talking to the FDA yet?” 
As a special treat for launching the new season, we have shared an extra segment exclusive to watch on the Phacilitate website.  
In this bonus clip, Anthony, Audrey and Bruce discuss the process (and best practice) for engaging the FDA in the product development pipeline for cell and gene therapies, sharing top tips and exclusive insights from their combined experience in cell and gene therapy development.  
The group discusses the idea that “perfect is the enemy of good” – a quote attributed to Peter Marks (CBER, FDA) from a recent ISCT meeting – outlining key issues associated with attitudes and approaches associated with the idea of perfection with cell and gene therapies, as well as the requirements for regulating them.  
Watch the bonus footage here: https://bit.ly/3krMrbI  
QUICK LINKS 
Bruce Levine: https://bit.ly/3DdC5oC  
Audrey Greenberg: https://bit.ly/3DhDxpR  
Anthony Davies: https://bit.ly/3B7EQpJ  
Christina Fuentes: https://bit.ly/2YSihaL 
Georgi Makin: https://bit.ly/2Wg7Qgl  
The opinions expressed in this podcast are solely those of the interviewees’ and do not necessarily reflect the views or opinions of their respective employers. 
This podcast has been produced in partnership with Dark Horse Consulting: https://darkhorseconsultinggroup.com/  

Welcome to the first episode of Phacilitate Talks!
Lindsey Clarke the European Head of Cell and Gene Therapy at bio-techne, Anthony Davies, CEO of Dark Horse Consulting and Cenk Sumen CTO of Stemson Therapeutics dig into how their teams have adjusted to remote work, how covid-19 has impacted clinical trials and what we do as global community to better prepare for the next pandemic.
 
In this episode I refer to a webinar with Kings College, Sexton Biotechnologies and BioBridge Global which you can sign up for here - https://bit.ly/2WkhOJs
 
If you’re not already, don’t forget to sign-up as a Phacilitate member, it’s FREE! Every fortnight you’ll get the latest market intelligence, new ideas and exclusive events offers straight to your inbox. Join a community with the same goal; to help advance a new standard in healthcare.
www.phacilitate.co.uk/subscribe